We held our first “Alltrna on the Lawn” last month. Lawn games in the sun, a few rounds of pickleball, and a good excuse to celebrate the last of summer together as “one team.” Life at Alltrna: alltrna.com/life-at-alltrna

At CSHL Translational Control, Alltrna scientist Jalyce Heller shared our research on engineering tRNAs to address disease-causing premature stop codons. tRNAs play an essential role in turning genetic instructions into proteins. When a premature stop codon interrupts those instructions, the cell can stop making a protein before it is complete. Our approach is to engineer tRNAs that recognize these stop codons, insert the intended amino acid, and allow protein production to continue. Jalyce’s work contributes to our understanding of how engineered tRNAs can be developed as medicines for #StopCodonDisease, including the potential to address the same underlying mutation across different genes and diseases. Learn more about tRNA biology and our approach: alltrna.com/trna-biology

At RNA Leaders USA, Alltrna CSO Dave Hava will share how preclinical work with AP003 is informing a mutation-defined clinical development strategy for Stop Codon Disease. AP003 is engineered to read through the Arg-TGA premature stop codon. In preclinical models of PKU and MMA, the same tRNA therapeutic restored the distinct full-length proteins disrupted in each disease. These findings support the potential to bring patients with different rare diseases into a common development program when they share the same underlying mutation, an approach that could help make development more feasible across rare and ultra-rare patient populations. Join Dave on Sept. 25 at 11:20am ET for “Advancing tRNA Therapeutics for Stop Codon Disease: Preclinical Data Supporting a Basket Clinical Development Strategy.” Learn more: informaconnect.com/rna-leade…

We’re looking forward to joining the tRNA community for the 30th tRNA Conference at a time when the therapeutic potential of tRNA is beginning to be explored in the clinic. Alltrna will share our work on premature stop codon readthrough, including the science supporting AP003, now being evaluated in the first clinical trial of a tRNA therapeutic. Bringing AP003 to this development stage has required work across tRNA biology, engineering, chemical modification, delivery, and manufacturing. The tRNA Conference has long been an important forum for bringing this scientific community together. We’re pleased to present at this year’s meeting and look forward to learning from colleagues across the field while sharing what we’ve learned along the way. Learn more about our lead program: alltrna.com/trna-medicines-p…

Throughout her career caring for children and developing medicines for rare diseases, Nerissa Kreher has met many families searching for a treatment option for their child or loved one. For many rare and ultra-rare diseases, small patient populations can make studying each disease separately difficult. Basket trials offer another potential path, bringing together people with different diseases that share the same underlying mutation and relevant clinical characteristics. On Labiotech’s Beyond Biotech podcast, Nerissa discusses why engineered tRNA medicines may be well suited to this approach, the clinical development of AP003, the first tRNA therapeutic to enter clinical trials, and the evidence needed to support future basket trials. Listen here: podcast.labiotech.eu/1995493…

A medicine designed to work across diseases demands a clinical development model built to do the same. Alltrna is developing engineered tRNA medicines around shared genetic mutations, creating the potential to bring patients with different diseases into a common development path. At the 2026 Rare Trials Summit, Alltrna Chief Medical Officer Nerissa Kreher, MD, MBA, will join the cross-track strategic plenary, “𝙋𝙡𝙖𝙩𝙛𝙤𝙧𝙢 𝙖𝙣𝙙 𝘽𝙖𝙨𝙠𝙚𝙩 𝙏𝙧𝙞𝙖𝙡𝙨 𝙞𝙣 𝙍𝙖𝙧𝙚 𝘿𝙞𝙨𝙚𝙖𝙨𝙚: 𝙒𝙝𝙖𝙩’𝙨 𝙒𝙤𝙧𝙠𝙞𝙣𝙜, 𝙒𝙝𝙖𝙩 𝙄𝙨𝙣’𝙩, 𝙖𝙣𝙙 𝙒𝙝𝙖𝙩 𝙄𝙩 𝙏𝙖𝙠𝙚𝙨 𝙩𝙤 𝙎𝙘𝙖𝙡𝙚.” The discussion will focus on the practical lessons shaping platform and basket trials in rare disease, including where these models are working, where challenges remain, and what it will take to make them viable at scale. See the agenda here: raretrialssummit.com/

Alltrna will be at ICIEM/SSIEM 2026 in Helsinki to share preclinical research from our AP003 program with the inherited metabolic disease community. For families affected by rare genetic diseases, the specific mutation behind a diagnosis can matter. A premature stop codon is a genetic change that tells the cell to stop making a protein too soon, which can leave the body without enough of the full-length protein it needs. At Alltrna, we’re developing engineered tRNA medicines designed to read through these premature stop codons so protein production can continue. Because the same stop codon mutation can occur in different genes and diseases, one tRNA medicine may have the potential to address patients across multiple rare diseases that share that mutation. Our poster at ICIEM/SSIEM includes preclinical data from AP003 in PKU and MMA, two rare inherited metabolic diseases that can be caused by the Arg-TGA premature stop codon. We’re looking forward to conversations with patients, families, clinicians, and researchers about what a mutation-defined approach could mean for rare disease drug development. Learn more about #StopCodonDisease: alltrna.com/stop-codon-disea…

For many families affected by rare disease, the question is not whether a treatment will be available soon, it is whether anyone will ever develop one for their disease. In a recent episode of She Leads Biotech, Alltrna Chief Medical Officer Nerissa Kreher, MD, MBA, discusses why answering that question requires a different model, one built around what diseases share rather than what separates them. At Alltrna, we are developing engineered tRNA medicines designed to address premature stop codons across different genes and diseases. This creates the potential for one medicine to reach groups of patients who have different rare diseases but share the same underlying mutation. The conversation also explores what is needed to put that approach into practice, including genetic testing to identify patients and clinical trial designs that can bring together people across multiple diseases. Listen to her full conversation with Sharron Cox from CNA USA Executive Search here: open.spotify.com/episode/3WT…

For World RNA Day, we're celebrating the remarkable biology of RNA, and the growing potential of transfer RNA (tRNA) as a new class of genetic medicine. While messenger RNA (mRNA) carries the genetic instructions for making proteins, transfer RNA (tRNA) plays an essential role in translating those instructions into functional proteins. For approximately 10% of people with a rare genetic disease, a premature stop codon interrupts that process, preventing cells from producing a full-length protein. At Alltrna, we're engineering tRNAs designed to read through premature stop codons by inserting the amino acid originally intended by the genetic code, allowing protein production to continue. This year marks an important milestone toward that goal, with engineered tRNA medicines now being evaluated in the first clinical trial. As a new therapeutic modality, they have the potential to help people across many different rare diseases that share the same underlying mutation, offering a path toward treating patients based on mutation rather than diagnosis. Learn more about the biology of tRNA and its therapeutic potential: alltrna.com/trna-biology #RNADay #WorldRNADay #StopCodonDisease

This summer, the Alltrna team stepped away from our usual routines and explored places near and far, from Amsterdam, Scotland, Turkey, and Zermatt to Chatham, Connecticut, Maine, and Nova Scotia. Our annual company-wide summer break gives everyone time to recharge in the way that works best for them, whether that means discovering a new city, spending time outdoors, or slowing down closer to home. We returned refreshed and ready to keep moving our work forward together. #WeAreAlltrna #LifeAtAlltrna

Alltrna is looking forward to participating in the 2026 NUCDF Family Conference and supporting the urea cycle disorder community. Our CMO, Dr. Nerissa Kreher, will present a poster on AP003, the first tRNA therapeutic in clinical development. AP003 is being developed for liver Stop Codon Disease and is currently in clinical evaluation in healthy volunteers. This study is an important step toward a potential Phase 2 basket trial that aims to include patients across multiple liver inborn errors of metabolism driven by Arg-TGA variants, including PKU, organic acidemias, and urea cycle disorders. We appreciate the @CureUCD's leadership in creating a space for education, connection, and continued progress for families affected by urea cycle disorders. To learn more about #StopCodonDisease, visit: alltrna.com/stop-codon-disea…

Alltrna is pleased to participate in the 2026 NPKUA Living Our Best PKU Life Community Conference, joining families, clinicians, advocates, and industry partners committed to supporting the PKU community. Our team will be on site at the Alltrna booth to talk about AP003, the first tRNA therapeutic in clinical development. AP003 is being developed for liver Stop Codon Disease, including PKU. We appreciate @NPKUA_Info's leadership in creating a space for education, connection, and continued progress for families affected by PKU. To learn more about #StopCodonDisease, visit: alltrna.com/stop-codon-disea…

This Pride Month, we celebrated inclusion, allyship, and the importance of creating a workplace where everyone feels seen, supported, and valued. At Alltrna, we know that different perspectives make our team stronger. Our Rainbow Ice Cream Social gave employees a chance to come together, reflect on what inclusion means to them, and contribute to our “Being an Ally” board. Thank you to everyone who helped make the celebration meaningful. #WeAreAlltrna

Alltrna will share preclinical data at the ASCEND 2026 Rett Syndrome National Summit, hosted by the @Rettsyndrome. YounKyoung Lee, Ph.D., will give a flash talk and share a poster highlighting engineered tRNAs as a potential therapeutic strategy for Rett syndrome caused by Arg-TGA premature stop codons. The data provide early support for engineered tRNAs as a potential strategy to restore full-length MECP2 production in Rett syndrome. By acting on the cell’s existing mRNA, engineered tRNAs may help support protein restoration in a way that preserves MECP2’s natural regulation, an important consideration for a dosage-sensitive protein. We appreciate IRSF’s leadership in bringing together researchers, clinicians, advocates, and families working to advance new possibilities for the #RettSyndrome community. To learn more about #StopCodonDisease, visit: alltrna.com/stop-codon-disea….

Alltrna celebrated Juneteenth by gathering over lunch, and we made sure to put our support behind a local Black-owned business while we did it. Beyond the food (which was incredible), we used the time to have real conversations about something that matters to our work: underrepresentation in biomedical research. It's an issue that directly impacts whose diseases get studied, whose treatments get developed, and who benefits from innovation. Building inclusive science isn't just the right thing to do. It's the smart thing to do. Diverse perspectives strengthen research. Diverse representation in clinical trials strengthens outcomes. And supporting our community strengthens all of us.

Precision in genetic medicine does not always have to mean one gene, one drug. It can also mean one mechanism, one drug. In this Q&A with Advancing RNA, Alltrna CMO Nerissa Kreher discusses how engineered tRNA therapeutics are being developed to address a shared genetic error, like premature stop codons, with the potential to support mutation-defined approaches across many diseases. advancingrna.com/doc/enginee… #tRNA #StopCodonDisease

At Alltrna, the best science happens when people feel connected to something bigger than the lab. We recently set up two AeroGardens, a traditional seed sowing station, and a sunny corner dedicated to dwarf cherry tomatoes, basil, and mint. Alltrnators came together to plant, decorate their pots, and nurture something new.

In approximately 10% of rare genetic diseases, the gene and RNA are present, but translation stops before a full-length protein can be made. In a new Q&A with Technology Networks, Alltrna CSO Dave Hava explains how engineered tRNA therapeutics can address shared translation errors by acting within the cell’s native translation machinery at the point where mRNA is decoded into protein. This creates the potential for mutation-defined drug development to restore full-length protein production across many rare and ultra-rare diseases that share the same genetic variant. Read more in @Tech_Networks: technologynetworks.com/prote…

At ASGCT 2026, Alltrna will give an oral presentation highlighting the potential of engineered tRNA therapeutics to restore full-length protein production across rare and ultra-rare genetic disorders caused by premature termination codons. The presentation will feature preclinical data from AP003, Alltrna’s lead clinical candidate, in phenylketonuria and methylmalonic acidemia models. The data support advancement of a single engineered tRNA therapeutic through a basket-enabled clinical strategy across liver inborn errors of metabolism that share an Arg-TGA premature termination codon. The full #ASGCT26 abstract is available online: annualmeeting.asgct.org/

Rare disease research often calls for clinical development strategies that can work across small, heterogeneous patient populations. Alltrna CMO Nerissa Kreher will give a keynote about how basket and umbrella trial approaches can help address these challenges, from recruitment and evidence generation to operational execution and regulatory alignment. Her talk at COG is Tuesday, April 28 at 9:30 am ET. See the agenda for more details: thepbcgroup.com/cog-new-engl…